USFDA has approved a drug from Boehringer Ingelheim Pharmaceuticals (BIPI) and Eli Lilly and Company to help control blood glucose in people with Type 2 diabetes.
Synjardy tablets consists of empagliflozin and metformin hydrochloride, with Empagliflozin a sodium glucose co-transporter-2 (SGLT2) inhibitor, removes excess glucose through the urine by blocking glucose re-absorption in the kidney. Metformin, a commonly prescribed initial treatment for T2D, lowers glucose production by the liver and its absorption in the intestine.
SYNJARDY is the third product containing empagliflozin to be approved by the FDA, following Jardiance® (empagliflozin) and Glyxambi® (empagliflozin/linagliptin).
“SYNJARDY is now the fifth FDA-approved medicine to emerge from the BI-Lilly Diabetes alliance pipeline in the last four years,” said Paul Fonteyne, president and CEO, BIPI. “No two people with diabetes are alike, and every experience is different. Our alliance is proud to offer a diverse portfolio of treatments that can help patients throughout their diabetes journey.”
SYNJARDY is indicated as an adjunct to diet and exercise to improve glycemic control in adults with T2D who are not adequately controlled on a regimen containing empagliflozin or metformin, or in patients already being treated with empagliflozin and metformin. SYNJARDY is not for the treatment of type 1 diabetes or diabetic ketoacidosis.
The FDA approval of SYNJARDY is based on results from multiple clinical trials examining the co-administration of empagliflozin and metformin, alone or in combination with sulfonylurea, in the treatment of adults with T2D.